What Is Cosyntropin?
Cosyntropin is a synthetic peptide consisting of the first 24 amino acids of naturally occurring ACTH (adrenocorticotropic hormone). ACTH is a hormone produced by the pituitary gland that signals the adrenal glands to manufacture and release cortisol, a critical steroid hormone involved in stress response, metabolism, and immune function.
The drug is marketed under the brand name Cortrosyn and is administered by injection—either intravenously or intramuscularly—in carefully controlled clinical settings. Because it's a peptide (a short chain of amino acids), it cannot be taken orally; the digestive system would break it down before it reached the bloodstream.
How Does Cosyntropin Work?
Cosyntropin functions through a mechanism called the cosyntropin stimulation test (also known as the ACTH stimulation test or short synacthen test). Here's the sequence:
- Baseline cortisol measurement: A doctor draws blood to measure your resting cortisol level.
- Cosyntropin injection: You receive a dose of cosyntropin (typically 250 micrograms intravenously).
- Timed response measurement: Blood is drawn again at 30 and 60 minutes post-injection to measure cortisol levels.
- Interpretation: A normal adrenal gland responds to cosyntropin by releasing a surge of cortisol. If cortisol fails to rise adequately, it suggests adrenal insufficiency.
The test works because cosyntropin binds to the same ACTH receptors on adrenal cells as the body's natural ACTH hormone. This binding triggers the cascade of biochemical events that leads to cortisol synthesis and release. The test is considered highly sensitive and specific for detecting primary adrenal insufficiency.
Clinical Evidence and Regulatory Status
Cosyntropin earned FDA approval in the 1970s based on extensive clinical validation. It remains one of the few peptides with the longest track record of safe, diagnostic use in medicine. The FDA classifies it as an approved drug with robust clinical evidence.
The regulatory landscape differs globally:
- United States: Full FDA approval for diagnostic use.
- European Union: Not authorised by the EMA, though some EU countries may permit it under national procedures.
- Canada: Not approved by Health Canada.
This approval status reflects cosyntropin's niche role: it's a specialized diagnostic tool, not a mass-market medication. The drug's narrow indication—adrenal function testing—means fewer regulatory pathways are required compared to therapeutics.
What Does the Research Show?
A comprehensive body of 38 clinical trials supports cosyntropin's diagnostic accuracy. The evidence grade is classified as A, the highest level, indicating robust, consistent findings across multiple studies.
Key research findings include:
Diagnostic Accuracy
Studies confirm that cosyntropin stimulation reliably identifies primary adrenal insufficiency with sensitivity exceeding 95%. This means the test rarely misses genuine cases of adrenal dysfunction. Specificity is similarly high, meaning false positives are uncommon.
Comparison to Other Tests
Cosyntropin's main diagnostic advantage is its ability to directly stimulate the adrenal cortex, bypassing the pituitary gland. This makes it superior for diagnosing primary adrenal insufficiency (failure of the adrenal glands themselves) versus secondary adrenal insufficiency (failure of pituitary or hypothalamic ACTH production). In secondary insufficiency, the adrenal glands may still respond to cosyntropin even though natural ACTH secretion is impaired.
Safety in Special Populations
Research demonstrates that cosyntropin is safe and effective across age groups, including pediatric and elderly populations. The peptide's short amino-acid chain (24 amino acids) minimizes allergic reactions compared to natural ACTH extracts.
Mechanism and Peptide Basis
Cosyntropin exemplifies a key principle in peptide therapeutics: synthetic peptides can replicate biological signaling with precision. By including only the first 24 amino acids of ACTH, researchers removed the portion most likely to trigger immune responses while retaining full receptor-binding capacity.
The peptide binds to melanocortin 2 (MC2) receptors on cells in the adrenal cortex, activating the same intracellular signaling cascade as natural ACTH. This leads to increased production of cortisol and other adrenal steroids. Because cosyntropin is synthetic and structurally defined, its purity and potency are consistent across every manufactured batch—an advantage over older ACTH preparations derived from animal pituitary tissue.
Clinical Applications
Cosyntropin is used to diagnose and evaluate:
Primary Adrenal Insufficiency (Addison's Disease)
When cortisol production fails due to autoimmune destruction or atrophy of adrenal tissue, cosyntropin stimulation produces little to no cortisol response. This helps clinicians distinguish primary insufficiency from other causes of low cortisol.
Secondary Adrenal Insufficiency
In conditions like pituitary adenomas or head trauma, the pituitary fails to produce ACTH, so the adrenal glands "atrophy from disuse." Cosyntropin can stimulate a delayed response, differentiating this from primary insufficiency where response is absent.
Post-Treatment Monitoring
Patients recovering from adrenal tumors or receiving long-term corticosteroid therapy are sometimes tested with cosyntropin to assess adrenal recovery. This helps guide decisions about steroid tapering and replacement therapy.
Safety Profile
Cosyntropin has an excellent safety record, with adverse events rare and typically mild. Common side effects, reported in fewer than 5% of patients, include mild flushing, transient elevation in heart rate, and local irritation at injection sites.
Serious allergic reactions are uncommon because:
- The peptide is synthetic (not derived from animals), reducing risk of contaminating proteins.
- The 24-amino-acid structure is recognized as "self-like" by the immune system.
- Doses used in diagnostic testing are small and short-acting.
Contraindications are minimal. Patients with a documented allergy to cosyntropin or excipients should avoid it. Pregnancy is not an absolute contraindication, though the test is typically deferred unless diagnosis is urgent.
How Cosyntropin Relates to Other Peptides
Cosyntropin sits in a unique category: it's a diagnostic peptide, not a therapeutic one. This distinguishes it from compounds like Abaloparatide, which treats osteoporosis, or research compounds like ARA-290, which are under investigation for tissue protection. Diagnostic peptides are administered once or a few times in a clinical setting under direct medical supervision, whereas therapeutic peptides may be used long-term by patients.
The peptide class itself—synthetic hormone analogues—also includes Alexamorelin, a growth hormone secretagogue used experimentally to stimulate GH release. Like cosyntropin, it exploits the body's natural signaling pathways, but for a different diagnostic or therapeutic purpose.
Regulatory Pathway and Manufacturing
Cosyntropin is manufactured by pharmaceutical companies under FDA oversight. The active pharmaceutical ingredient (API) is synthesized through standard peptide chemistry: amino acids are linked sequentially in precise order, then the chain is purified, characterized, and formulated into sterile injectable solutions.
Because cosyntropin is an FDA-approved drug, it can only be dispensed by licensed pharmacies and must be prescribed by a physician. It is not available over-the-counter and is not part of the research compound market.
Clinical Trial Landscape
With 38 registered clinical trials, cosyntropin has one of the most extensively studied diagnostic peptide profiles. Historical trials established its efficacy; modern trials increasingly focus on refining diagnostic thresholds, comparing it to newer biomarkers, and validating its use in underserved populations (e.g., critical illness, sepsis-associated adrenal insufficiency).
The high trial count also reflects its long history: many trials predate modern trial registries, so the 38 figure likely underrepresents the total body of evidence.
Practical Considerations
Timing and Preparation
Cosyntropin testing is usually performed in the morning, when cortisol levels follow their natural rhythm. Patients typically fast and avoid strenuous activity beforehand. The entire test takes 60–90 minutes.
Cost and Access
As an FDA-approved diagnostic drug, cosyntropin is covered by most insurance plans when ordered by a physician for a clinically indicated reason (e.g., suspected adrenal insufficiency). Out-of-pocket costs vary but are typically lower than specialized imaging or genetic testing.
Interpretation Tips
Normal cosyntropin response typically means cortisol rises to >18–20 mcg/dL within 30 minutes of injection. Results below this threshold suggest adrenal insufficiency. However, interpretation depends on clinical context and reference ranges used by the testing laboratory.
The Future of Adrenal Testing
While cosyntropin remains the gold standard, research is exploring alternative diagnostic approaches, such as measurement of 17-hydroxyprogesterone and ACTH-to-cortisol ratios. However, cosyntropin's simplicity, safety, and established clinical utility ensure its continued role in medicine for decades to come.
The peptide also serves as a model for rational drug design: by taking a natural hormone and streamlining it to its functional core (the first 24 amino acids), researchers created a tool that is simultaneously more reliable, safer, and easier to manufacture than its natural counterpart.
Bottom Line
Cosyntropin is a masterclass in peptide medicine: a synthetic peptide that replicates a natural hormone signal with precision, enabling accurate diagnosis of a serious but treatable condition. With FDA approval, extensive clinical validation, and an excellent safety record, it represents the mature, evidence-based application of peptide science in clinical practice.